Literature DB >> 2472164

Use of a carbocyanine dye as a marker of functional vasculature in murine tumours.

M J Trotter1, D J Chaplin, P L Olive.   

Abstract

An intravenously administered fluorescent carbocyanine dye, DiOC7(3), has been evaluated for use in conjunction with Hoechst 33342 as a marker of murine tumour vasculature. DiOC7(3) stains cells immediately adjacent to blood vessels and thus, like Hoechst 33342, outlines perfused tumour vasculature. The different fluorescence excitation and emission properties of DiOC7(3) and Hoechst 33342 permit discrimination of the stains in the same tissue section. Mice tolerate a DiOC7(3) dose of 1 mg kg-1 i.v. with no ill effects. The dye has a distribution half-life in blood of 180s and staining of perivascular tumour cells is sufficiently stable to allow visualisation of vasculature for up to 30 min after DiOC7(3) injection. However, DiOC7(3) causes a 75% reduction in tumour blood flow as measured by laser Doppler techniques. Consequently, the compound appears to be most suitable as a second vascular marker, administered at some time after Hoechst 33342, to detect temporal and spatial fluctuations in tumour perfusion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472164      PMCID: PMC2247238          DOI: 10.1038/bjc.1989.148

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  THE VASCULAR SPACE OF GROWING TUMORS.

Authors:  P M GULLINO; F H GRANTHAM
Journal:  Cancer Res       Date:  1964-11       Impact factor: 12.701

2.  Quantitative techniques for study of the anatomy and function of small blood vessels in tumors.

Authors:  I F Tannock; G G Steel
Journal:  J Natl Cancer Inst       Date:  1969-05       Impact factor: 13.506

3.  In vivo fluorescence of endothelial cell nuclei stained with the dye Bis-benzamide H 33342.

Authors:  H S Reinhold; J W Visser
Journal:  Int J Microcirc Clin Exp       Date:  1983

4.  Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation.

Authors:  J M Brown
Journal:  Br J Radiol       Date:  1979-08       Impact factor: 3.039

5.  Oxygenation and reoxygenation in 'sandwich' tumours.

Authors:  H S Reinhold; B Blachiwiecz; A Blok
Journal:  Bibl Anat       Date:  1977

6.  Dynamics of microvascular flow in implanted mouse mammary tumours.

Authors:  M Intaglietta; R R Myers; J F Gross; H S Reinhold
Journal:  Bibl Anat       Date:  1977

7.  Intermittent blood flow in a murine tumor: radiobiological effects.

Authors:  D J Chaplin; P L Olive; R E Durand
Journal:  Cancer Res       Date:  1987-01-15       Impact factor: 12.701

8.  Acute hypoxia in tumors: implications for modifiers of radiation effects.

Authors:  D J Chaplin; R E Durand; P L Olive
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

9.  Cell selection from a murine tumour using the fluorescent probe Hoechst 33342.

Authors:  D J Chaplin; R E Durand; P L Olive
Journal:  Br J Cancer       Date:  1985-04       Impact factor: 7.640

10.  Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours.

Authors:  P L Olive; D J Chaplin; R E Durand
Journal:  Br J Cancer       Date:  1985-11       Impact factor: 7.640

View more
  21 in total

1.  Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models.

Authors:  Arindam Sen; Maegan L Capitano; Joseph A Spernyak; John T Schueckler; Seneca Thomas; Anurag K Singh; Sharon S Evans; Bonnie L Hylander; Elizabeth A Repasky
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

2.  Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs.

Authors:  Arup Bhattacharya; Mukund Seshadri; Steven D Oven; Károly Tóth; Mary M Vaughan; Youcef M Rustum
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

3.  Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors.

Authors:  Sumit Bhatnagar; Emily Deschenes; Jianshan Liao; Cornelius Cilliers; Greg M Thurber
Journal:  J Pharm Sci       Date:  2014-07-21       Impact factor: 3.534

4.  Use of labeled tomato lectin for imaging vasculature structures.

Authors:  Richard T Robertson; Samantha T Levine; Sherry M Haynes; Paula Gutierrez; Janie L Baratta; Zhiqun Tan; Kenneth J Longmuir
Journal:  Histochem Cell Biol       Date:  2014-12-23       Impact factor: 4.304

5.  The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study.

Authors:  R D Blumenthal; I Fand; R M Sharkey; O C Boerman; R Kashi; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response.

Authors:  Bruce M Fenton; Scott F Paoni
Journal:  Radiat Res       Date:  2009-05       Impact factor: 2.841

Review 7.  Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow.

Authors:  Robert J Gillies; Joel S Brown; Alexander R A Anderson; Robert A Gatenby
Journal:  Nat Rev Cancer       Date:  2018-09       Impact factor: 60.716

8.  In vivo cancer imaging by poly(ethylene glycol)-b-poly(ɛ-caprolactone) micelles containing a near-infrared probe.

Authors:  Hyunah Cho; Guilherme L Indig; Jamey Weichert; Ho-Chul Shin; Glen S Kwon
Journal:  Nanomedicine       Date:  2011-06-24       Impact factor: 5.307

9.  Hydroethidine: a fluorescent redox probe for locating hypoxic cells in spheroids and murine tumours.

Authors:  P L Olive
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

10.  The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels.

Authors:  L J Zwi; B C Baguley; J B Gavin; W R Wilson
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.